A. Ferrieri

1.2k total citations
25 papers, 811 citations indexed

About

A. Ferrieri is a scholar working on Epidemiology, Surgery and Gastroenterology. According to data from OpenAlex, A. Ferrieri has authored 25 papers receiving a total of 811 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Epidemiology, 10 papers in Surgery and 6 papers in Gastroenterology. Recurrent topics in A. Ferrieri's work include Gastroesophageal reflux and treatments (6 papers), Pneumocystis jirovecii pneumonia detection and treatment (6 papers) and Eosinophilic Esophagitis (4 papers). A. Ferrieri is often cited by papers focused on Gastroesophageal reflux and treatments (6 papers), Pneumocystis jirovecii pneumonia detection and treatment (6 papers) and Eosinophilic Esophagitis (4 papers). A. Ferrieri collaborates with scholars based in Italy, United Kingdom and Canada. A. Ferrieri's co-authors include E. Trespi, Gilberto Poggioli, Maddalena Rossi, Risto Johansson, Federica Ugolini, Paolo Gionchetti, Massimo Campieri, Patrizia Brigidi, A. Venturi and Fernando Rizzello and has published in prestigious journals such as Alimentary Pharmacology & Therapeutics, Pharmacological Research and Scandinavian Journal of Gastroenterology.

In The Last Decade

A. Ferrieri

25 papers receiving 788 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Ferrieri Italy 15 425 328 229 205 151 25 811
C. J. McIver Australia 13 139 0.3× 195 0.6× 118 0.5× 101 0.5× 78 0.5× 23 685
Shoma Dutt Australia 11 373 0.9× 526 1.6× 97 0.4× 63 0.3× 673 4.5× 30 1.0k
J A Vanderhoof United States 11 272 0.6× 111 0.3× 113 0.5× 35 0.2× 218 1.4× 24 943
Carolina Palmela Portugal 14 375 0.9× 471 1.4× 104 0.5× 185 0.9× 599 4.0× 40 1.3k
M. G. Menozzi Italy 11 185 0.4× 183 0.6× 184 0.8× 22 0.1× 50 0.3× 18 668
A. Venturi Italy 12 213 0.5× 307 0.9× 138 0.6× 26 0.1× 414 2.7× 19 696
Kinga Kowalska‐Duplaga Poland 16 165 0.4× 188 0.6× 91 0.4× 43 0.2× 297 2.0× 43 736
Makbule Eren Türkiye 14 164 0.4× 100 0.3× 172 0.8× 24 0.1× 63 0.4× 41 686
Noortje Rossen Netherlands 7 244 0.6× 466 1.4× 424 1.9× 83 0.4× 288 1.9× 12 1.3k
A D Dwarakanath United Kingdom 11 146 0.3× 141 0.4× 41 0.2× 15 0.1× 200 1.3× 15 578

Countries citing papers authored by A. Ferrieri

Since Specialization
Citations

This map shows the geographic impact of A. Ferrieri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Ferrieri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Ferrieri more than expected).

Fields of papers citing papers by A. Ferrieri

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Ferrieri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Ferrieri. The network helps show where A. Ferrieri may publish in the future.

Co-authorship network of co-authors of A. Ferrieri

This figure shows the co-authorship network connecting the top 25 collaborators of A. Ferrieri. A scholar is included among the top collaborators of A. Ferrieri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Ferrieri. A. Ferrieri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Salaroli, Roberta, Domenico Ventrella, Chiara Bernardini, et al.. (2020). <p>Barrier Effect of a New Topical Agent on Damaged Esophageal Mucosa: Experimental Study on an ex vivo Swine Model</p>. Clinical and Experimental Gastroenterology. Volume 13. 569–576. 4 indexed citations
2.
Baldi, Fabio, et al.. (2012). Barrier effect of Esoxx&reg; on esophageal mucosal damage: experimental study on ex-vivo swine model. Clinical and Experimental Gastroenterology. 5. 103–103. 40 indexed citations
3.
Venturini, I., A. Ferrieri, Federico Farina, et al.. (2005). Evaluation of rifaximin, placebo and lactulose in reducing the levels of benzodiazepine-like compounds in patients with liver cirrhosis: a pilot study.. PubMed. 31(4). 161–8. 15 indexed citations
4.
Biancone, Livia, et al.. (2000). Effect of Rifaximin on Intestinal Bacterial Overgrowth in Crohn's Disease as Assessed by the H2-Glucose Breath Test. Current Medical Research and Opinion. 16(1). 14–20. 27 indexed citations
5.
Stefano, M. Di, Alessandra Strocchi, Simona Malservisi, et al.. (2000). Non‐absorbable antibiotics for managing intestinal gas production and gas‐related symptoms. Alimentary Pharmacology & Therapeutics. 14(8). 1001–1008. 76 indexed citations
6.
Biancone, Livia, et al.. (2000). Effect of Rifaximin on Intestinal Bacterial Overgrowth in Crohn's Disease as Assessed by the H<SUB>2</SUB>-Glucose Breath Test. Current Medical Research and Opinion. 16(1). 14–20. 3 indexed citations
7.
Ferrieri, A., et al.. (2000). A randomized openly comparative study between rifaximin suspension versus rifaximin pills for the eradication of Helicobacter pylori.. PubMed. 3(3). 105–10. 10 indexed citations
8.
Gionchetti, Paolo, Fernando Rizzello, A. Venturi, et al.. (1999). Antibiotic combination therapy in patients with chronic, treatment‐resistant pouchitis. Alimentary Pharmacology & Therapeutics. 13(6). 713–718. 179 indexed citations
9.
Trespi, E. & A. Ferrieri. (1999). Intestinal Bacterial Overgrowth During Chronic Pancreatitis. Current Medical Research and Opinion. 15(1). 47–52. 67 indexed citations
10.
Colomba, Claudia, et al.. (1999). Intestinal Protozoa in HIV-Infected Patients: Effect of Rifaximin inCryptosporidium parvumandBlastocystis hominisInfections. Journal of Chemotherapy. 11(5). 391–395. 46 indexed citations
11.
Zeneroli, Maria Luisa, I. Venturini, Federico Farina, et al.. (1997). ANTIBACTERIAL ACTIVITY OF RIFAXIMIN REDUCES THE LEVELS OF BENZODIAZEPINE-LIKE COMPOUNDS IN PATIENTS WITH LIVER CIRRHOSIS. Pharmacological Research. 35(6). 557–560. 21 indexed citations
12.
Miglio, F, et al.. (1997). Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial. Current Medical Research and Opinion. 13(10). 593–601. 72 indexed citations
13.
Puxeddu, A, et al.. (1995). Rifaximin in the treatment of chronic hepatic encephalopathy. Current Medical Research and Opinion. 13(5). 274–281. 38 indexed citations
14.
Ferrieri, A., et al.. (1995). The natural history of diverticular disease of the colon: a role for antibiotics in preventing complications? A retrospective study.. PubMed. 16(1-2). 33–9. 15 indexed citations
15.
Giaccari, S, et al.. (1994). Long-term treatment with rifaximin and lactobacilli in post-diverticulitic stenoses of the colon.. PubMed. 15(1). 29–34. 39 indexed citations
16.
Sciarretta, G, A Furno, M. Mazzoni, A. Ferrieri, & P Malaguti. (1993). Scintigraphic Study of Gastrointestinal Transit and Disintegration Sites of Mesalazine Tablets Labeled with Technetium-99m. Scandinavian Journal of Gastroenterology. 28(9). 783–785. 9 indexed citations
17.
Ferrieri, A., et al.. (1993). [Dietetic therapy of obesity. Preliminary considerations on the combined therapy with ursodeoxycholic acid in the prevention of cholesterol lithiasis].. PubMed. 84(5). 269–74. 1 indexed citations
18.
Festi, Davide, G. Mazzella, S. Sottili, et al.. (1993). Rifaximin in the treatment of chronic hepatic encephalopathy; results of a multicenter study of efficacy and safety. Current Therapeutic Research. 54(5). 598–609. 57 indexed citations
19.
Bresadola, F, et al.. (1992). [Chemotherapeutic prophylaxis in the preparation of the large intestine for surgical interventions: rifaximin P.O. vs. cephalosporin I.V].. PubMed. 63(2). 201–7. 4 indexed citations
20.
Riegler, Gabriele, et al.. (1992). [Clinical-therapeutic considerations in the treatment of aspecific abdominal disturbances in patients with ulcerative colitis in remission: preliminary note on therapy with rifaximin].. PubMed. 14(1). 9–14. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by C. J. McIver Breakdown of academic impact, for papers by Shoma Dutt Breakdown of academic impact, for papers by J A Vanderhoof Breakdown of academic impact, for papers by Carolina Palmela Breakdown of academic impact, for papers by M. G. Menozzi Breakdown of academic impact, for papers by A. Venturi Breakdown of academic impact, for papers by Kinga Kowalska‐Duplaga Breakdown of academic impact, for papers by Makbule Eren Breakdown of academic impact, for papers by Noortje Rossen Breakdown of academic impact, for papers by A D Dwarakanath
Rankless by CCL
2026